CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company's aim of transforming the lives of people with cancer. B ...

New facility is expected to serve as a global hub for accelerating the development of next-generation antibody-drug ...

Boehringer Ingelheim subsidiary NBE Therapeutics has opened its new antibody-drug conjugates (ADC) R&D facility in Basel, ...

Boehringer Ingelheim opened a €60m ($66.8m) research building in Vienna, Austria, in September 2024, signalling the company's intention to expand its presence in the oncology sector.

Boehringer Ingelheim, via its subsidiary NBE Therapeutics, has launched a cutting-edge ADC research and development facility in Basel with a CHF ...

2 Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria. 3 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States. The authors would like to thank Jane Saunders of Ashfield ...

Basel, Switzerland Friday, April 4, 2025, 10:00 Hrs [IST] ...